Avastin scintigraphy in surveillance of bevacizumab treatment in a patient with neurofibromatosis type 2: a case report.
A patient with neurofibromatosis type 2 (bilateral vestibular schwannomas) was treated with bevacizumab (anti-vascular endothelial growth factor [VEFG] monoclonal antibody). The left-sided tumor showed intense uptake on pretreatment In-bevacizumab scintigraphy, indicating VEGF production in the tumor, and no uptake 4 weeks later, demonstrating effective binding of nonradiolabeled bevacizumab to the VEGF produced in the tumor. The right-sided tumor showed no tracer uptake at any time point. Significant tumor volume reduction (assessed with MRI) and hearing improvement were observed on the left side. In-bevacizumab scintigraphy may be a promising upfront patient selection tool to identify patients who may benefit from expensive bevacizumab treatment.
From the Departments of *Nuclear Medicine, †Radiology, ‡Ear Nose and Throat, and §Medical Oncology, Radboud University Medical Centre, Nijmegen, the Netherlands.
Michelle W J
MW
Versleijen
Berit M
BM
Verbist
Jef J S
JJ
Mulder
Lioe-Fee
LF
de Geus-Oei
Carla M L
CM
van Herpen
D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068258:Bevacizumab; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D016518:Neurofibromatosis 2 / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D009464:Neuroma, Acoustic / Q000000981:diagnostic imaging / Q000188:drug therapy; D011877:Radionuclide Imaging
D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab